Enterprise Value
1.123B
Cash
506.5M
Avg Qtr Burn
N/A
Short % of Float
18.67%
Insider Ownership
7.39%
Institutional Own.
93.17%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CART-ddBCMA Details Multiple myeloma | Phase 2 Data readout | |
ACLX-001 (ARC-SparX program) Details Multiple myeloma | Phase 1 Data readout | |
ACLX-002 (ARC-SparX program) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 1 Update |